SynthesisClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Neutrophil-to-lymphocyte ratio in unresectable or metastatic esophageal squamous cell carcinoma: a systematic review, meta-analysis and meta-regression.
Synthesis in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNeutrophil-to-lymphocyte ratio (NLR) is a widely studied variable to investigate the systemic inflammation-related prognostic effect, and in some clinical setting has been able to predict the activity of immunotherapy. Many studies confirmed a negative relationship of pre-treatment high NLR and the outcome of patients with esophageal squamous cell cancer (ESCC), but poor data are available for patients with unresectable or metastatic ESCC (mESCC). The study aims to perform a trial-level analysis of the relationship of NLR with overall survival (OS) among mESCC patients receiving an upfront systemic treatment.
methodsA systematic literature review of studies enrolling mESCC patients receiving an upfront chemotherapy-based regimen and reporting the hazard ratio and confidence intervals of the relationship of NLR with OS were carried out. A meta-analysis was performed, calculating a global effect size, and another one evaluated only immunotherapy-based studies. Finally, based on the resulting between-study heterogeneity, a meta-regression evaluated the possible inference of the more frequently reported baseline variables on the relationship.
resultsTwenty-three articles, including 24 study cohorts, were selected, including 3590 patients. The meta-analysis calculated a significant effect size for the relationship of NLR with OS (HR 2.01, CI 1.64-2.45), that was maintained among the 16 immunotherapy-based studies (HR 2.12, CI 1.58-2.84). The significant heterogeneity between studies (Q = 126.24, p-value < 0.0001; I
conclusionsBaseline NLR is a reliable prognostic factor of mESCC patients receiving upfront chemotherapy-based regimens, with a lightly more pronounced effect size when the regimen included.
Indexed as
Identifiers
41703395What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.